DEEP RESEARCH · Caregen
Caregen: Peptide Platform and 2026 Pipeline Momentum
A platform view of CG-P5, Korglutide, and a debt-light financial structure
0. Bottom line first
Caregen is moving from cosmeceuticals toward a peptide-based drug and nutraceutical platform. CG-P5 offers an eye-drop option for wet AMD, Korglutide offers an oral weight-management material, and a 48.6% operating margin with virtually no debt gives the company internal funding power for trials and R&D.
Official fact: The source says Caregen received and disclosed the U.S. Phase 1 CSR for CG-P5 on December 30, 2025, with 45 wAMD patients across six U.S. clinical sites.
Interpretation: In Phase 1 the key point is safety and tolerability, not definitive efficacy. The source emphasizes that self-administered CG-P5 eye drops showed a placebo-like safety profile, potentially supporting Phase 2 and licensing discussions.
1. CG-P5: Eye-Drop Optionality in an Injection Market
The source treats the inclusion of Eylea as a positive control as strategically important. Eylea was administered monthly by intravitreal injection, while CG-P5 was self-administered once daily as eye drops.
| Item | CG-P5 | Existing anti-VEGF injections |
|---|---|---|
| Route | Self-administered eye drops | Intravitreal injection |
| Phase 1 focus | Safety and tolerability met per source | Standard of care but invasive |
| Source watch point | Double-layered delivery safety in ocular tissue | Pain, infection, clinic-visit burden |
- Adverse events: ocular and non-ocular AEs were described as similar to placebo in frequency and severity.
- IOP: no intraocular-pressure rise was observed according to the source.
- Inflammation: no meaningful difference versus placebo was described.
- Systemic safety: vital signs, hematology, and urinalysis showed no abnormal findings per the source.
2. Korglutide: Speed Through the NDI Route
Official fact: The source says Korglutide showed about 10.78% weight loss in 12 weeks in Phase 3 and consists of a seven-amino-acid small peptide structure.
Interpretation: Caregen's strategy is not the conventional NDA drug route but FDA NDI approval as a nutraceutical, aiming to shorten commercialization time. The 2022 ProGsterol NDI precedent is used as support.
Access
The target is an OTC diet product available without a prescription.
Oral positioning
It addresses the inconvenience and side-effect concerns of injectable GLP-1 products.
FDA judgment
Synthetic peptide and obesity-related positioning may trigger conservative review.
3. Financials: Unusual Cash Generation for Biotech
| Item | Q3 2025 cumulative source figure | Read-through |
|---|---|---|
| Revenue | About KRW 56.5 billion · down about 7.7% YoY | Cosmetics/filler demand slowdown and distributor reset |
| Operating profit | About KRW 27.5 billion · OPM 48.6% | In-house peptide manufacturing and vertical integration |
| Net income | About KRW 23.4 billion · net margin 41.4% | Operating profit converts well to net income |
| Operating cash flow | KRW 15.7 billion inflow | Core business still generates cash |
| Dividends | About KRW 31.1 billion paid | Shareholder return and liquidity confidence |
| Debt ratio | 8.58% | Virtually debt-free |
| Mezzanine | No CB/BW balance | Limited overhang risk |
4. Risks and 2026 Watch Points
- Partnership volatility: Korglutide supply-contract changes in Iraq and the Middle East show emerging-market uncertainty.
- Regulatory risk: delay or rejection of Korglutide NDI approval could raise short-term volatility.
- Competition: Eylea biosimilars and Vabysmo are already present in the wAMD market.
- Core checkpoints: Korglutide NDI approval and launch, CG-P5 Phase 2 entry, and global pharma partnerships.
Sources
- Original post: https://m.blog.naver.com/PostView.naver?blogId=star_of_self&logNo=224128349709
- Reference: https://drive.google.com/open?id=1EFcSqFsgsdOBqn27RblXPrXZdULIL5Z_ucVOan8zpwI
- Reference: https://comp.wisereport.co.kr/company/c1010001.aspx?cmp_cd=214370
- Reference: https://biz.chosun.com/science-chosun/bio/2025/10/28/IY2UPWA5F5FJPGGIMK6CBPHI3U/
- Reference: https://www.monews.co.kr/news/articleView.html?idxno=332067
- Reference: https://www.thepublic.kr/news/articleView.html?idxno=281268
- Reference: https://ng.investing.com/pro/KOSDAQ:A214370/financials/cashflow_statement
- Reference: https://pitchbook.com/profiles/company/163097-74
- Reference: https://www.alm.com/press_release/alm-intelligence-updates-verdictsearch/?s-news-19887629-2025-12-09-korean-pharma-to-cease-obesity-treatment-offerings-in-iraq-amid-market-challenges
- Reference: https://www.kndaily.co.kr/news/articleView.html?idxno=307809
- Reference: https://www.venturesquare.net/en/1025705